Mezzion Pharmaceuticals is dedicated to improving outcomes for patients with rare congenital heart diseases, particularly those with single ventricle heart disease and Fontan circulation
Mezzion Pharmaceuticals is dedicated to improving outcomes for patients with rare congenital heart diseases, particularly those with single ventricle heart disease and Fontan circulation. The company focuses on discovering, developing, and delivering new treatments, including the drug JURVIGO® (udenafil), which aims to enhance exercise capacity and quality of life for Fontan patients.